Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an in…


ADx NeuroSciences shifts into higher gear

Plenty of good news for ADx NeuroSciences. Today, the Ghent-based Alzheimer specialist has announced the end of its third capital round as well as…


36 million euros for neurostimulation of spinal cord

The Swiss-Dutch company G-therapeutics, a spin-off from École Polytechnique Fédérale de Lausanne (EPFL), has announced that it received €36 millio…

POPULAR TAGS

Regeneron's anti-NGF mAb meets Phase II/III endpoint

Written by LVS on in the category news with the tags .


Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said fasinumab (REGN475) met the primary endpoint of significantly improving pain relief vs. placebo in a Phase II/III study to treat moderate to severe osteoarthritis (OA) pain of the hip or knee. The study enrolled 421 patients with a history of inadequate pain relief or intolerance to current analgesic therapies.

Through week 16, Regeneron said the overall incidence of adverse events was similar across the fasinumab and placebo groups, but there was an increase in some neuro-musculoskeletal adverse events in the fasinumab groups (17% combined for all doses vs. 6% for placebo). Regeneron did not respond to an inquiry about a partial clinical hold FDA had placed on fasinumab.

Two other anti-NGF mAbs are also in late-stage studies to treat pain: tanezumab (PF-4383119) jointly owned by Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co. (NYSE:LLY) and fulranumab (AMG403), owned by Amgen Inc. (NYSE:AMGE).

Full article available at BioCentury.

Read more about: .

RELATED ARTICLES
Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an in…


ADx NeuroSciences shifts into higher gear

Plenty of good news for ADx NeuroSciences. Today, the Ghent-based Alzheimer specialist has announced the end of its third capital round as well as…


36 million euros for neurostimulation of spinal cord

The Swiss-Dutch company G-therapeutics, a spin-off from École Polytechnique Fédérale de Lausanne (EPFL), has announced that it received €36 millio…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Janssen KU Leuven UGent Flanders.bio GSK Turnstone XpandInnovation Biowin V-Bio Ventures Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.